These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 2323360)

  • 21. Q-fever soluble vaccine effects in Coxiella burneti sensitized humans.
    Crăcea E; Dumitrescu-Constantinescu S; Botez D; Ioanid L
    Zentralbl Bakteriol Orig A; 1977 Jul; 238(3):413-8. PubMed ID: 910580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination of cattle workers at risk of Q fever on the north coast of New South Wales.
    Hutson B; Deaker RA; Newland J
    Aust Fam Physician; 2000 Jul; 29(7):708-9. PubMed ID: 10914459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term immune responses to Coxiella burnetii after vaccination.
    Kersh GJ; Fitzpatrick KA; Self JS; Biggerstaff BJ; Massung RF
    Clin Vaccine Immunol; 2013 Feb; 20(2):129-33. PubMed ID: 23192629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreasing prevalence of Q fever in Illinois.
    Martin RJ; Schnurrenberger PR; Ferris DH; Hanger PN; Morrissey RA
    Public Health Rep; 1982; 97(2):170-4. PubMed ID: 7063599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the cells involved in the lymphoproliferative response to Coxiella burnetii antigens.
    Izzo AA; Marmion BP; Hackstadt T
    Clin Exp Immunol; 1991 Jul; 85(1):98-108. PubMed ID: 2070564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the efficacy of human Q fever vaccine registered in Australia.
    Chiu CK; Durrheim DN
    N S W Public Health Bull; 2007; 18(7-8):133-6. PubMed ID: 17854543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Q fever vaccine efficacy and occupational exposure risk in Queensland, Australia: A retrospective cohort study.
    Woldeyohannes SM; Perkins NR; Baker P; Gilks CF; Knibbs LD; Reid SA
    Vaccine; 2020 Sep; 38(42):6578-6584. PubMed ID: 32798141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunity in Q fever.
    Kazár J
    Acta Virol; 1988 Jul; 32(4):358-68. PubMed ID: 2903642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control strategies for Q fever based on results of pre-vaccination screening in Victoria, 1988 to 2001.
    Greig JE; Patel MS; Clements MS; Taylor NK
    Aust N Z J Public Health; 2005 Feb; 29(1):53-7. PubMed ID: 15782873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a phase I Coxiella burnetii inactivated vaccine on body temperature and milk yield in dairy cows.
    Schulze LS; Borchardt S; Ouellet V; Heuwieser W
    J Dairy Sci; 2016 Jan; 99(1):541-50. PubMed ID: 26547657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-mediated immune response to Coxiella burnetii antigens in Q fever convalescents and vaccinees.
    Gajdosová E; Brezina R
    Acta Virol; 1989 Sep; 33(5):474-81. PubMed ID: 2576587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Q fever (Coxiella burnetii) investigations in dairy cattle: persistence of antibodies after vaccination.
    Behymer DE; Biberstein EL; Riemann HP; Franti CE; Sawyer M
    Am J Vet Res; 1975 Jun; 36(6):781-84. PubMed ID: 1147331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin responses to Coxiella burnetii (Q fever): single-serum diagnosis of acute infection, using an immunofluorescence technique.
    Hunt JG; Field PR; Murphy AM
    Infect Immun; 1983 Feb; 39(2):977-81. PubMed ID: 6339396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-mediated immune responses of guinea pigs to an inactivated phase I Coxiella burnetii vaccine.
    Kishimoto RA; Johnson JW; Kenyon RH; Ascher MS; Larson EW; Pedersen CE
    Infect Immun; 1978 Jan; 19(1):194-8. PubMed ID: 624586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization against Q-fever of naturally infected dairy cows.
    Sádecký E; Brezina R; Kazár J; Urvölgyi J
    Acta Virol; 1975 Nov; 19(6):486-8. PubMed ID: 1994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol.
    Waag DM; England MJ; Tammariello RF; Byrne WR; Gibbs P; Banfield CM; Pitt ML
    Vaccine; 2002 Jun; 20(19-20):2623-34. PubMed ID: 12057622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetti for the immunization of animals.
    Williams JC; Peacock MG; Waag DM; Kent G; England MJ; Nelson G; Stephenson EH
    Ann N Y Acad Sci; 1992 Jun; 653():88-111. PubMed ID: 1626897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Components of protective immunity.
    Zhang G; Zhang Y; Samuel JE
    Adv Exp Med Biol; 2012; 984():91-104. PubMed ID: 22711628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii.
    Waag DM; England MJ; Bolt CR; Williams JC
    Clin Vaccine Immunol; 2008 Oct; 15(10):1505-12. PubMed ID: 18701647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of Q fever in Australia 1991-1994.
    Garner MG; Longbottom HM; Cannon RM; Plant AJ
    Aust N Z J Public Health; 1997 Dec; 21(7):722-30. PubMed ID: 9489189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.